Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate of the combination of bortezomib
and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic
Syndromes (MDS).